Trial Profile
A phase 3, randomized, double-blind, placebo-controlled, multicenter study of visilizumab in subjects with intravenous steroid-refractory ulcerative colitis
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 02 Jun 2011
Price :
$35
*
At a glance
- Drugs Visilizumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Abbott Biotherapeutics Corp; PDL BioPharma
- 06 Oct 2009 New trial record.